Literature DB >> 32158926

Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia.

David Sharon1, Steven M Chan1.   

Abstract

Venetoclax, a selective B-cell lymphoma 2 inhibitor, has shown promise in the treatment of acute myeloid leukemia. However, the development of drug resistance limits its clinical efficacy. In our study, we discovered that ribosome-targeting antibiotics can be repurposed to overcome venetoclax resistance in AML cells through activation of the integrated stress response.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Acute myeloid leukemia; BCL-2 inhibitor; antibiotics; drug resistance; integrated stress response; mitochondrial translation

Year:  2020        PMID： 32158926      PMCID： PMC7051130          DOI： 10.1080/23723556.2020.1712182

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  8 in total

1.  When true enough is not good enough.

Authors: 
Journal:  Nat Med       Date:  2013-01       Impact factor: 53.440

2.  Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research.

Authors:  Norman Moullan; Laurent Mouchiroud; Xu Wang; Dongryeol Ryu; Evan G Williams; Adrienne Mottis; Virginija Jovaisaite; Michael V Frochaux; Pedro M Quiros; Bart Deplancke; Riekelt H Houtkooper; Johan Auwerx
Journal:  Cell Rep       Date:  2015-03-12       Impact factor: 9.423

3.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

4.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Authors:  Rongqing Pan; Leah J Hogdal; Juliana M Benito; Donna Bucci; Lina Han; Gautam Borthakur; Jorge Cortes; Daniel J DeAngelo; Lakeisha Debose; Hong Mu; Hartmut Döhner; Verena I Gaidzik; Ilene Galinsky; Leonard S Golfman; Torsten Haferlach; Karine G Harutyunyan; Jianhua Hu; Joel D Leverson; Guido Marcucci; Markus Müschen; Rachel Newman; Eugene Park; Peter P Ruvolo; Vivian Ruvolo; Jeremy Ryan; Sonja Schindela; Patrick Zweidler-McKay; Richard M Stone; Hagop Kantarjian; Michael Andreeff; Marina Konopleva; Anthony G Letai
Journal:  Cancer Discov       Date:  2013-12-17       Impact factor: 39.397

5.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

6.  Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B.

Authors:  Alisa F Zyryanova; Félix Weis; Alexandre Faille; Akeel Abo Alard; Ana Crespillo-Casado; Yusuke Sekine; Heather P Harding; Felicity Allen; Leopold Parts; Christophe Fromont; Peter M Fischer; Alan J Warren; David Ron
Journal:  Science       Date:  2018-03-30       Impact factor: 47.728

7.  Potential mechanisms of resistance to venetoclax and strategies to circumvent it.

Authors:  Stephen K Tahir; Morey L Smith; Paul Hessler; Lisa Roberts Rapp; Kenneth B Idler; Chang H Park; Joel D Leverson; Lloyd T Lam
Journal:  BMC Cancer       Date:  2017-06-02       Impact factor: 4.430

8.  Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals.

Authors:  Pedro M Quirós; Miguel A Prado; Nicola Zamboni; Davide D'Amico; Robert W Williams; Daniel Finley; Steven P Gygi; Johan Auwerx
Journal:  J Cell Biol       Date:  2017-05-31       Impact factor: 10.539
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.